银屑病生物制剂治疗与严重感染风险的相关性
结果显示,阿达木单抗和英夫利西单抗的严重感染风险高于依那西普,乌司奴单抗风险较低,而IL-17抑制剂、IL-23抑制剂古塞奇尤单抗和阿普斯特未见风险升高。
要点
- 阿达木单抗和英夫利西单抗的严重感染风险高于依那西普。
- 乌司奴单抗的严重感染风险低于依那西普。
- IL-17抑制剂、古塞奇尤单抗和阿普斯特未见严重感染风险升高。
核心结论
- 与依那西普相比,英夫利西单抗和阿达木单抗新使用者的严重感染风险增加,乌司奴单抗使用者风险较低。
- IL-17抑制剂、IL-23抑制剂古塞奇尤单抗和阿普斯特新使用者未见严重感染风险增加。
研究设计与样本
- 法国全国队列研究,数据来自覆盖约99%法国人口的国家健康数据系统,纳入2008年1月1日至2019年5月31日期间注册的成人银屑病患者。
- 研究人群为生物制剂或阿普斯特的新使用者,排除HIV感染、癌症史、移植史或严重感染史者,随访至2020年1月31日。
主要发现
- 共发生1656例严重感染,总体粗发病率为25.0(95% CI 23.8-26.2)/1000人年。
- 最常见的严重感染为胃肠道感染(645例,38.9%)。
- 与依那西普相比,阿达木单抗的加权风险比(wHR)为1.22(95% CI 1.07-1.38),英夫利西单抗为1.79(95% CI 1.49-2.16)。
- 乌司奴单抗的wHR为0.79(95% CI 0.67-0.94)。
- IL-17抑制剂、IL-23抑制剂古塞奇尤单抗和阿普斯特与依那西普相比,严重感染风险未见增加。
关键数值与推荐
- 主要终点为严重感染,采用倾向评分加权Cox比例风险回归模型估计加权风险比(wHR)和95% CI。
- 合并使用非甾体抗炎药或全身性糖皮质激素与严重感染风险增加相关。
临床怎么用
- 对于中重度银屑病患者,选择生物制剂时应考虑严重感染风险,英夫利西单抗和阿达木单抗风险高于依那西普。
- 乌司奴单抗、IL-17抑制剂、古塞奇尤单抗和阿普斯特可作为严重感染风险较低的选择。
- 应避免不必要的合并使用非甾体抗炎药或全身性糖皮质激素,以降低严重感染风险。
局限性
- 需要其他观察性研究来确认最新药物的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Biologics and targeted therapies, such as apremilast, are efficient treatments to manage moderate to severe psoriasis. More information about the risk of serious infection is needed for the newest treatment options in a real-world setting. OBJECTIVE: To assess the risk of serious infection among biologics and apremilast used to treat psoriasis, with etanercept as the comparator. DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study from France involved data from the National Health Data System covering approximately 99% of the French population. All adults with psoriasis, defined as receiving at least 2 prescriptions of a topical vitamin D derivative within a 2-year period, registered in the database between January 1, 2008, and May 31, 2019, were eligible. The study population included those who were new users of biologic agents or apremilast (ie, without any prescriptions of a biologic or apremilast during the previous year). Patients with HIV infection or a history of cancer, transplant, or serious infection were excluded. End of follow-up was January 31, 2020. MAIN OUTCOME MEASURES: The primary end point was a serious infection in a time-to-event analysis using propensity score-weighted Cox proportional hazards regression models, estimating weighted hazard ratios (wHRs) and 95% CIs. RESULTS: A total of 44 239 new users of biologic treatment were identified (mean [SD] age, 48.4 [13.8] years; 22 866 [51.7%] men; median follow-up, 12 months [interquartile range, 7-24 months]). A total of 29 618 (66.9%) were prescribed a tumor necrosis factor inhibitor first, 6658 (15.0%) an interleukin (IL) 12/23 inhibitor, 4093 (9.3%) an IL-17 inhibitor, 526 (1.2%) an IL-23 inhibitor, and 3344 (7.6%) apremilast. The total number of serious infections was 1656, and the overall crude incidence rate was 25.0 (95% CI, 23.8-26.2) per 1000 person-years. The most frequent serious infections were gastrointestinal infections (645 patients [38.9%]). After adjusting for time-dependent covariables, risk of serious infections was higher for new users of adalimumab (wHR, 1.22; 95% CI, 1.07-1.38) or infliximab (wHR, 1.79; 95% CI 1.49-2.16) vs etanercept, whereas ustekinumab was associated with a lower risk of having a serious infection (wHR, 0.79; 95% CI, 0.67-0.94). Risk of serious infections was not increased for new users of IL-17 and the IL-23 inhibitor guselkumab or apremilast vs etanercept. Risk of serious infections was increased with concomitant nonsteroidal anti-inflammatory drugs or systemic corticosteroids. CONCLUSIONS AND RELEVANCE: In this cohort study of individuals with moderate to severe psoriasis, risk of serious infections was increased in new users of infliximab and adalimumab vs etanercept, whereas ustekinumab users had lower risk of having a serious infection but not new users of IL-17 and IL-23 inhibitors or apremilast. Other observational studies are needed to confirm results for the most recent drugs.
引用
- Penso L, Dray-Spira R, Weill A, et al. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis. JAMA Dermatol. 2021. PMID: 34287624. doi:10.1001/jamadermatol.2021.2599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。